Department of Orthopaedics, Chengdu Military General Hospital, Chengdu, Sichuan Province 610036, China.
Department of Orthopaedics, Fuping Couty Hospital, Fuping, Shaanxi Province, 711700, China.
Curr Stem Cell Res Ther. 2019;14(3):226-229. doi: 10.2174/1574888X13666181025120252.
Osteonecrosis of the femoral head (ONFH) is a common refractory orthopedic disease with multiple etiologies that more frequently occurs in middle-aged and young people. ONFH is the main cause of hip replacement in young patients. Since Professor Hernigou first reported the use of stem cells in the treatment of early stage ONFH, a large number of studies have demonstrated the potential of stem cells in the treatment of adult patients with ONFH. With the rise of interdisciplinary stem cell therapy combined with platelet-rich plasma therapy, gene therapy or other methods have gradually attracted the attention of researchers. This article summarizes the current advances in stem cell therapy for ONFH, as well as the problems and challenges, which may provide reference for further research.
股骨头坏死（ONFH）是一种常见的难治性骨科疾病，病因多样，多见于中青年人。ONFH 是中青年患者髋关节置换的主要原因。自 Hernigou 教授首次报道干细胞治疗早期 ONFH 以来，大量研究表明干细胞在治疗成人 ONFH 患者方面具有潜力。随着干细胞治疗与富血小板血浆疗法等多种方法联合的交叉学科的兴起，基因治疗等方法逐渐受到研究人员的关注。本文就 ONFH 的干细胞治疗的研究进展、存在的问题和挑战进行综述，以期为进一步研究提供参考。
